MEI Pharma Inc(MEIP)stock report

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and ME-401. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. ME-401 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Market Cap:160.2M; Shares Outstanding:73.7M; Q1 2020(3/31/19): Cash 65.92M. Loss 2.99M

EPS and Sales:

Date EPS % last year % last quarter
2019.6.30 -0.04 90.00% 425.00%
2019.9.30 -0.28 50.00% -600.00%
2019.12.31 -0.24 75.26% 14.29%
 2020.3.31 -0.04 80.95% 83.33%


Date Sales % last year % last quarter
2019.6.30 2.54M 295.63% 418.37%
2019.9.30 3.79M 252.42% 49.21%
2019.12.31 4.92M 203.02% 29.82%
 2020.3.31 1.16M 137.09% -76.42%


Insider Transactions:

Institution Ownership:

Total institutions: 81,no change
Shares hold: 42.55k shares. no change
shares% hold: 41.81%,no change

Analyst Ratings:

Leave a Reply